Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy

Proactive - Interviews for investors

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to share news the company has announced promising PET scan results from a patient with moderate Alzheimer’s disease treated for three months with intranasal foralumab under an expanded access program. The scan revealed a significant reduction in microglial activation, a key marker of neuroinflammation linked to Alzheimer’s progression. This outcome represents a major milestone for the company’s intranasal foralumab program. With no approved therapies for moderate Alzheimer’s disease, Tiziana sees foralumab—a fully human anti-CD3 monoclonal antibody—as a potential treatment option, both as a monotherapy and in combination with amyloid-targeting therapies. Foralumab has shown the ability to induce regulatory T cells (Tregs) that migrate to the brain and suppress neuroinflammation. These effects have been validated in preclinical models and in patients with secondary progressive multiple sclerosis, supporting further clinical development in neurodegenerative conditions. The company is set to begin a Phase 2 randomized, placebo-controlled trial in June 2025 involving mild Alzheimer’s patients. Data from this trial are expected by the end of 2025. The aim is to determine if reducing neuroinflammation translates into improved quality of life. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation